

<b>General information about company</b>	
Name of The Company	MARKSANS PHARMA LIMITED
BSE Scrip Code	524404
NSE Symbol	MARKSANS
MSE Symbol	NA
Date of Start of Financial Year	01-04-2022
Date of End of Financial Year	31-3-2023
Reporting Period	First half yearly
Date of Start of Reporting Period	01-04-2022
Date of End of Reporting Period	30-09-2022
Level of rounding to be used in disclosing related party transactions	Millions
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the banks/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
<b>(b) If answer to above question is No, please explain the reason for not complying.</b>	

**Related party transactions**

Related party transactions													Additional disclosure of related party transactions relates to loans, inter-corporate deposits, advances or investments. These details need to be disclosed			
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure
1	Marksans Pharma Limited	AAACT3153G	Nova Pharmaceuticals Australasia Pty Ltd	ZZZZZ9999Z	Subsidiary	Sale of goods or services		297.9	The transactions are within the limit of omnibus approval granted by the Audit Committee	297.9	0	0				
2	Marksans Pharma Limited	AAACT3153G	Bell, Sons and Co. (Druggists) Limited	ZZZZZ9999Z	Wholly-owned Subsidiary	Sale of goods or services			Nil	402.99	0	0				
3	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Wholly-owned Subsidiary	Sale of goods or services			Nil	459.89	0	0				
4	Marksans Pharma Limited	AAACT3153G	Time-Cap Laboratories Inc	ZZZZZ9999Z	Wholly-owned Subsidiary	Sale of goods or services			Nil	1589.57	0	0				
5	Marksans Pharma Limited	AAACT3153G	Time-Cap Laboratories Inc.	ZZZZZ9999Z	Wholly-owned Subsidiary	Any other transaction	Guarantee		Nil	0.99	0	0				
6	Marksans Pharma Limited	AAACT3153G	Nova Pharmaceuticals Australasia Pty Ltd	ZZZZZ9999Z	Subsidiary	Any other transaction	Trade Receivable		Nil	0	295.44	382.77				
7	Marksans Pharma Limited	AAACT3153G	Bell, Sons and Co. (Druggists) Limited	ZZZZZ9999Z	Wholly-owned Subsidiary	Any other transaction	Trade Receivable		Nil	0	-171.82	-43.29				
8	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Wholly-owned Subsidiary	Any other transaction	Trade Receivable		Nil	0	-365.51	-544.62				

9	Marksans Pharma Limited	AAACT3153G	Time-Cap Laboratories Inc.	ZZZZ9999Z	Wholly-owned Subsidiary	Any other transaction	Trade Receivable		Nil	0	1919.41	2220.64				
10	Marksans Pharma Limited	AAACT3153G	Time-Cap Laboratories Inc.	ZZZZ9999Z	Wholly-owned Subsidiary	Any other transaction	Trade Payable		Nil	0	0.05	-0.05				
11	Marksans Pharma Limited	AAACT3153G	Mr. Mark Saldanha	AHAPS0915M	Promoter & Key Managerial Personnel	Any other transaction	Rent Paid	5.33	Nil	5.33	0	0				
12	Marksans Pharma Limited	AAACT3153G	Mr. Mark Saldanha	AHAPS0915M	Promoter & Key Managerial Personnel	Remuneration		26.05	Nil	26.05	0	0				
13	Marksans Pharma Limited	AAACT3153G	Mrs. Sandra Saldanha	ALRPS8186P	Promoter & Key Managerial Personnel	Remuneration			Nil	3.51	0	0				
14	Marksans Pharma Limited	AAACT3153G	Mr. Varddhman Vikramaditya Jain	ACWPJ0702A	Key Managerial Personnel	Remuneration			Nil	8.37	0	0				
15	Marksans Pharma Limited	AAACT3153G	Mr. Jitendra Sharma	AJCPS5121K	Key Managerial Personnel	Remuneration			Nil	7.68	0	0				
16	Marksans Pharma Limited	AAACT3153G	Mr. Harshavardhan Panigrahi	AKTPP1644A	Key Managerial Personnel	Remuneration			Nil	1.27	0	0				
17	Marksans Pharma Limited	AAACT3153G	Mr. Abhinna Sundar Mohanty	AAAPM5371J	Non-executive Director	Any other transaction	Sitting Fees		Nil	0.01	0	0				
18	Marksans Pharma Limited	AAACT3153G	Mr. Seetharama Raju Bhuddharaju	ABLPB6474F	Non-executive Director	Any other transaction	Sitting Fees		Nil	0.01	0	0				
19	Marksans Pharma Limited	AAACT3153G	Mr. Digant Mahesh Parikh	AAFPP7379G	Non-executive Director	Any other transaction	Sitting Fees		Nil	0.05	0	0				
20	Marksans Pharma Limited	AAACT3153G	Mrs. Meena Rani Surana	ENDPS0915Q	Non-executive Director	Any other transaction	Sitting Fees		Nil	0.01	0	0				
21	Time-Cap Laboratories Inc	ZZZZ9999Z	Mr. Mark Saldanha	AHAPS0915M	Director	Remuneration			Nil	5.65	0	0				
22	Marksans Pharma Limited	AAACT3153G	Marksans Pharma U.K. Limited	ZZZZ9999Z	Wholly-owned Subsidiary	Dividend received			Nil	108.33	0	0				
Total value of transaction during the reporting period										2917.61						

